Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 28Gastrointestinal 18Genitourinary 9Sarcoma 7Breast 6Other solid neoplasm 5Head & Neck 5Gynecologic 3Dermatologic 3Lymphoid 2Tumor-Agnostic 1Plasma cell 1NET 1Endocrine 1CNS 1

Conditions

Melanoma 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Nivolumab 24pembrolizumab 22Ipilimumab 17Specimen Handling 15Magnetic Resonance Spectroscopy 9CTLA-4 Antigen 8Opdualag 7relatlimab 6Cyclophosphamide 6binimetinib 5Paclitaxel 5trametinib 4fludarabine phosphate 4fludarabine 4cemiplimab 4Carboplatin 4Biopsy 4lifileucel 3dabrafenib 3atezolizumab 3X-Rays 3Taxes 3Standard of Care 3Radiotherapy 3Radiation 3Pemetrexed 3Introns 3Interferon alpha-2 3Immunoglobulin G 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
atezolizumab × Dermatologic × 30 days × Clear all
NCT05110781 2026-06-05

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

University of California, Davis

Phase 2 Terminated
1 enrolled 9 charts
DermatologicHead & Neck

Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT06066138 2026-06-04

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
30 enrolled
DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT03289962 2026-05-29

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Genentech, Inc.

Phase 1 Completed
273 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡